Last reviewed · How we verify
SARS-Cov-2 Vaccine Inactivated — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
SARS-Cov-2 Vaccine Inactivated (SARS-Cov-2 Vaccine Inactivated) — Livzon Pharmaceutical Group Inc.. This vaccine works by introducing inactivated SARS-Cov-2 virus to stimulate an immune response.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SARS-Cov-2 Vaccine Inactivated TARGET | SARS-Cov-2 Vaccine Inactivated | Livzon Pharmaceutical Group Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SARS-Cov-2 Vaccine Inactivated CI watch — RSS
- SARS-Cov-2 Vaccine Inactivated CI watch — Atom
- SARS-Cov-2 Vaccine Inactivated CI watch — JSON
- SARS-Cov-2 Vaccine Inactivated alone — RSS
Cite this brief
Drug Landscape (2026). SARS-Cov-2 Vaccine Inactivated — Competitive Intelligence Brief. https://druglandscape.com/ci/sars-cov-2-vaccine-inactivated. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab